The role and application of small extracellular vesicles in gastric cancer

Hao Wu 1, Mengdi Fu 2, Jin Liu 3, Wei Chong 1,4,5, Zhen Fang 1,4,5, Fengying Du 1, Yang Liu 1, Liang Shang 1,4,5* and Leping Li 1,4,5*

Abstract

Gastric cancer (GC) is a common tumour that affects humans worldwide, is highly malignant and has a poor prognosis. Small extracellular vesicles (sEVs), especially exosomes, are nanoscale vesicles released by various cells that deliver bioactive molecules to recipient cells, affecting their biological characteristics, changing the tumour microenvironment and producing long-distance effects. In recent years, many studies have clarified the mechanisms by which sEVs function with regard to the initiation, progression, angiogenesis, metastasis and chemoresistance of GC. These molecules can function as mediators of cell-cell communication in the tumour microenvironment and might affect the efficacy of immunotherapy. Due to their unique physiochemical characteristics, sEVs show potential as effective antitumour vaccines as well as drug carriers. In this review, we summarize the roles of sEVs in GC and highlight the clinical application prospects in the future.

Keywords: Gastric cancer, Small extracellular vesicles, Exosomes, Diagnosis, Therapy, Molecular mechanism

Introduction

As one of the most common malignant tumours, gastric cancer (GC) affects the physical and mental health of those at risk. In a report released by the International Agency for Research on Cancer, the worldwide incidence of GC ranks fifth among all tumours, and mortality ranks fourth [1]. Asia, especially East Asia, has a high incidence of GC. As patients with early GC typically have no symptoms, they often miss the opportunity for optimal treatment. With the advancement of endoscopy technology, an increasing number of GC cases are being diagnosed early, but the invasiveness and high cost of endoscopy restrict large-scale GC screening. At present, there is still a lack of noninvasive and highly accurate tumour biomarkers, which can strongly support for the screening of GC, even in the early stages. Despite considerable recent progress in surgical treatment, endoscopic treatment, chemotherapy, radiotherapy, and targeted therapy, the prognosis of patients with advanced GC remains poor, causing a major burden on families and society. Therefore, the application of more indicators of risk and prognosis is urgently needed.

Small extracellular vesicles (sEVs), broadly present nano-scale vesicle structures secreted by almost all cells, can transmit information between cells and participate in their physiological and pathological processes. Due to their unique structural characteristics, sEVs have become hot research topics in recent years, and their role in the initiation and progression of GC is gradually being clarified.

A few years ago, two review articles [2, 3] gave a detailed summary of the role of extracellular vehicles (EVs) or exosomes in GC, which was important and caused an increase in exosome research in the field of GC. Currently, the structure, related technologies and mechanisms of exosomes are being discovered and applied. Most importantly, the International Society for Extracellular Vesicles issued guidelines at the end of 2018 to standardize the nomenclature of extracellular vesicles. Most methods used to isolate exosomes...
currently co-isolate heterogeneous populations of EVs of diverse biogenic origins. For accuracy and clarity, we refer to “sEVs”, typically called “exosomes” in publications, as small cell-derived membrane vesicles in accordance with the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) guidelines [4].

This review focused on emphasizing the major advancements in the past few years to reveal the role and application of sEVs in GC. A systematic literature search of Embase, PubMed, Web of Science, and Clinicaltrials.gov was performed for relevant publications up to 1 March 2021. MISEV 2018 guidelines were followed to screen literature about “Stomach Neoplasms”[Mesh], “Exosomes”[Mesh], and “small extracellular vesicles”.

The biological origin and structural characteristics of EVs

In 1983, John Stone et al. observed the process by which sheep reticulocytes transform into mature red blood cells and found that red blood cells release transferrin metabolites through some small vesicles, which were initially considered to be cell debris but were later confirmed to be separate structures and named exosomes [5]. Early endosomes are generated after inward budding of the plasma membrane and then transform into multivesicular bodies (MVBs) when membrane vesicles form by budding [6]. MVBs participate in the process of endocytosis and transport of intracellular materials, which involves the sorting, recovery, storage, transportation and release of proteins. MVBs are finally sent to the lysosome for degradation or fuse with the cell membrane and are released into the extracellular environment in a form called exosomes [7]. The most common hypothesis is that the endosomal sorting complex required for transport (ESCRT) family catalyses exosome budding [8]; however, there is no substantive decrease in exosome biogenesis after inhibition of ESCRT family activity [9]. In addition, ESCRT-independent mechanisms, such as heterogeneous nuclear ribonucleoprotein-dependent pathways and neutral sphingomyelinase 2-dependent pathways, were found to affect the formation of exosomes [10]. Recently, Kang et al. [11] identified a novel ESCRT-independent mechanism marked and controlled by RAB31, which has improved our understanding of exosome biogenesis (Fig. 1).

Exosomes are single-cell membrane vesicles with a lipid bilayer membrane structure, a size of approximately 30–150 nm and a density of approximately 1.13–1.21 g/ml [12]. Exosomes are derived from almost all human cells and are widely present in various body fluids, such as blood, saliva, bile, and urine. They can be produced by almost all cell types, including cancer cells, immune cells, and fibroblasts. Exosomes play a crucial role in cell-to-cell communication by transferring proteins, lipids, RNA, and DNA to recipient cells. They are involved in various biological processes, including the regulation of immune responses, metabolism, and cell survival.

**Fig. 1** The biogenesis and compositions of exosomes. Golgi apparatus could produce lipid rafts, which facilitate endocytosis. Early endosomes (EE) are formed after the inward budding of the plasma membrane, then they transport from early to late endosomes (LE), which transforming into multivesicular bodies (MVBs) when membrane vesicles sprout inward the cavity. Secretion or degradation is under control of ESCRT family and ESCRT-independent RAB31. Cholesterol-rich (CHL-R) and RAB31-high pre-exosomes are destined to secreted as exosomes, while cholesterol deficient (CHL-D) and RAB31-low are degraded. Exosomes contain complex contents such as proteins, mRNA, miRNA, IncRNA, and DNA. Some protein biomarkers are used to characterize exosomes currently.
as blood, urine, cerebrospinal fluid, tears, saliva, milk, ascites, lymph, and amniotic fluid [13].

Plasma membrane-derived ectosomes, also called microparticles or microvesicles, which are 100–1000 nm in diameter, may have largely analogous functions to exosomes [14]. Apoptotic bodies, also called apoptotic vesicles, can be observed when cells undergo apoptosis and may also be confused with other EVs [15].

The function of EVs mainly depends on their rich and complex cargo, of which approximately 76% comprises proteins and 15% mRNAs; the remaining components include DNAs, microRNAs (miRNAs), circular RNAs (circRNA) and long noncoding RNAs (IncRNAs) [16–20].

However, without optimal separation strategies and specific markers of different sources of EVs at present, it is difficult to propose specific and universal markers of MVB-derived “exosomes” compared with other small EVs. The term “exosomes” was used to refer to EV preparations that have been separated from larger EVs, which refer to a mixture of sEVs of both exosomal and non-exosomal particles [21]. We used “small extracellular vesicles” (diameter < 200 or < 100 nm) in place of “exosomes” according to MISEV2018 [4].

**Separation, characterization and storage of sEVs**

A variety of protocols have been applied to the separation of sEVs [22, 23]. Differential ultracentrifugation is currently the most commonly used technique for sEV separation [24]. In addition, other classic techniques, such as density gradients [25], immunoisolation [26], precipitation [27] and filtration [28], are applied. Each method has advantages and disadvantages regarding recovery, specificity, time and cost [29, 30]. Although a number of novel techniques have been developed recently [31–34], absolute isolation of sEVs is still unrealistic, and combinations of methods will continue to be recommended.

Similarly, the identification of sEVs is complicated. Both the source of EVs and the EV preparation must be described quantitatively, according to MISEV2018. Protein content-based EV characteristics are routinely detected and analysed. Positive proteins must include at least one transmembrane/lipid-bound protein (usually CD9, CD63, CD83 and integrin) and one cytosolic protein recovered in EVs (usually ALIX, TSG101, syntenin and HSP70). The levels of at least one negative protein, such as albumin, lipoproteins, and ribosomal proteins, should also be determined. In addition, analysis of functional proteins, such as histones, cytochrome C, calnexin or Grp94, is required when claiming specific analysis of sEVs [4].

Western blotting is the most commonly used method and can detect both surface and internal proteins. Fluorescence microscopes can detect these structures labelled with specific fluorescent probes [35]. Flow cytometry can also be used but is restricted by the small size of sEVs and the low abundance of surface antigens [36]. Mass spectrometry has become economical and accessible in recent years [37]. However, a large number of sEVs are required for protein extraction, which reduces efficiency [6]. At least two different but complementary techniques are also recommended for characterization of the heterogeneity of single vesicles, such as transmission electron microscopy or atomic force microscopy [38].

The storage conditions of sEVs are also very important and may affect their characteristics. There is currently no general consensus that the original samples from which sEVs are extracted should be stored at −80°C and used as soon as possible when conducting experiments [39, 40].

**The relationship between sEVs and GC**

EVs play a relatively important role in the tumorigenesis of GC [41], and their effects on invasion, metastasis, angiogenesis, immune escape, and chemotherapy resistance have been confirmed by several studies (Fig. 2). In 2009, Qu et al. first reported that the sEVs of GC cells can at least partially promote tumour cell proliferation through the PI3K/Akt pathway and MAPK/ERK activation. Metabolism involving the Cbl ubiquitin ligase family and Caspases may also participate in this process [42, 43]. In 2012, Gu et al. confirmed that the TGF-β/Smad pathway mediated by sEVs triggers the differentiation of umbilical cord mesenchymal stem cells into cancer-related fibroblasts. CD97 is also thought to promote the proliferation and invasion of GC cells, and its ability to promote lymphatic metastasis in GC is related to sEVs [44, 45]. In addition, GC cell-derived sEVs can induce infiltration of peritoneal mesothelial cells (PMCs), and infiltrating PMCs in turn promote tumour subserosal invasion [46]. Overall, the interaction between cancer cells and PMCs accelerates gastric wall invasion and peritoneal metastasis. EVs also have an important role in the tumour microenvironment. For example, GC cell-derived sEVs stimulate the phosphorylation of NF-κB in macrophages to promote cancer progression [47] and induce the production of PD-1+ tumour-associated macrophages (TAMs), which is beneficial for tumour angiogenesis and metastasis [48]. A similar mechanism of action was reported by Shen et al. [49], and sEVs promote the polarization of N2 tumour-associated neutrophils to induce autophagy and increase tumour activation, promoting GC migration [50]. Ji et al. [51] and Wang et al. [52] revealed the role of sEVs in 5-Fluorouracil (5-FU) and platinum resistance. These studies contribute to the discovery and application of potential alternative drugs to reverse resistance.

Although the study of sEVs related to GC is still in early stages, the quantity and quality of related research have improved recently, providing new insight into the
mechanisms underlying the initiation and progression of GC. In the following sections, we discuss the interaction between GC and sEV cargo in the tumour microenvironment and in GC cells to provide a comprehensive understanding of the relationship between them.

**sEVs and GC initiation & progression**

The initiation and progression of cancer are often affected by the mutual influence of tumour cells or the microenvironment, but the mechanism is not completely clear. Under physiological and pathological conditions, sEVs are released from the cell membrane, and the biologically active substances carried as cargo are involved in many processes (Table 1).

Although many studies have explored the relationship between sEVs and early gastric cancer, only a few articles have clarified the mechanism of sEVs in gastric carcinogenesis. Yoon et al. [55] identified Gastrokine 1 (GKN1) through a protein microarray in 2018 and found that it binds to 27 sEV proteins. GKN1 in sEVs can inhibit the proliferation of a variety of GC cells and induce apoptosis, and the results were supported in vitro. After further research, GKN1 was confirmed to be a tumour suppressor that reduces the initiation of GC by decreasing activation of the Hras/Raf/MEK/ERK signalling pathway, but its specificity is high, and the same effect has not been found in other gastrointestinal tumours [71]. Wei et al. [57] used qRT-PCR to show that miR-15b-3p is highly expressed in tissues, serum, cells and sEVs, enhancing the tumorigenesis and malignant transformation of GC by inhibiting the NYDLT1/Caspase-3/Caspase-9 pathway and suppressing apoptosis in GC. Based on these findings, it was proposed that miR-15b-3p can serve as a diagnostic and prognostic biomarker for GC. In addition, more articles have elucidated the mechanism of tumorigenesis through the exploration of the microenvironment, which we will describe later in the article.

Regarding the malignant behaviours of tumour cells, such as proliferation and invasion, many molecules have also been discovered. The FZD protein family of receptors in the Wnt signalling pathway plays an important role in gastrointestinal tumours. In cells with silencing
of Frizzled 10 (FZD10) expression, addition of FZD10 and FZD10 mRNA restored viability. FZD10 has been shown to be a potential messenger of cancer reactivation and may play an equally active role in distant metastasis [53]. Mesenchymal stem cells (MSCs) are present in the tumour microenvironment. The N-recognin 2 (UBR2) component of ubiquitin protein ligase E3 can be delivered to target cells by sEVs to promote the growth and metastasis of GC [54]. Both GC tissue-induced mesenchymal stem cells [58] and bone marrow-induced mesenchymal stem cells [59] have been reported to significantly promote the growth and migration of GC cells through paracrine miR-221, the expression levels of which are closely related to lymphatic metastasis, venous infiltration and TNM staging. For instance, low expression of IncRNA SPRY4-IT1 caused dividing GC cells to stagnate in G1 phase, inhibiting the proliferation of GC cells. Overexpression of IncRNA SPRY4-IT1 promoted cell migration and invasion through the SPRY4-IT1/miR-101-3p/AMPK axis. SPRY4-IT1 has been shown to be transported in sEVs and is related to the progression and metastasis of GC [64].

Zhang et al. [68] detected an increased level of circNRP1 expression in GC through RNA-seq analysis and showed that it has a tumour-promoting effect. Subsequently, the circNRP1-miR-149-5p-AKT1/mTOR axis was found to be an important mechanism that promotes the proliferation, migration and invasion of GC, as determined by Western blot analysis and immunofluorescence. In addition, this molecule enhanced the stability of VEGF mRNA, as proven by in vivo and in vitro experiments. Moreover, circSHKB1 can directly bind to HSP90 and hinder its interaction with STUB1, inhibiting the ubiquitination of HSP90 and promoting the proliferation, migration, invasion and angiogenesis of GC cells [69]. Recently, Zhang et al. showed that degradation of miR-30a or miR-30b could be induced by HOTAIR to promote the carcinogenesis of GC [72]. In addition, other cargo [60–62, 65–67, 70] plays a role in tumorigenesis and tumour progression.

Tumour cells develop significantly faster than vascular cells due to their strong proliferation, so hypoxia is often observed, and oxygen-monitoring mechanisms might be activated [73]. Xia et al. [63] found that hypoxia GC-

### Table 1: Role of sEVs cargo in initiation and progression of GC

| Type    | Contents          | Donor cells                     | Recipient cells        | Function                                                                 | Ref. |
|---------|-------------------|--------------------------------|------------------------|--------------------------------------------------------------------------|------|
| protein | CD97              | SGC-7901                        | SGC-7901               | Promote cell proliferation and invasion                                   | [45] |
| protein | FZD10             | HGC-27 and N-87                 | HGC-27 and N-87        | Sustain cancer cell proliferation                                         | [53] |
| protein | UBR2              | p53−/− mBMMSC and MFC           | p53−/− mBMMSC and MFC  | Promote cell proliferation, migration, and stemness                      | [54] |
| protein | GKN1              | HFE-145                         | AGS and MKN1           | Inhibit gastric tumorigenesis                                             | [55] |
| protein | TRIM3             | Overexpressed MGC-803 and SGC-7901 | MGC-803 and SGC-7901 | Suppress GC growth                                                        | [56] |
| miRNA   | mir-15b-3p        | SGC-7901 and BGC-823            | SGC-7901 and BGC-823   | Enhance tumorigenesis and malignant transformation                        | [57] |
| miRNA   | mir-221           | GC-MSCs                         | HGC-27                 | Promote cell proliferation and migration                                  | [58] |
| miRNA   | mir-221           | BM-MSCs                         | BGC-823 and SGC-7901   | Enhance cell proliferation, migration, invasion, and adhesion to the matrix | [59] |
| miRNA   | mir-1290          | SGC-7901 and AGS                | SGC-7901 and AGS       | Promote proliferation and invasion                                         | [60] |
| miRNA   | mir-423-5p        | SGC-7901 and HGC-27            | SGC-7901 and HGC-27    | Promote cancer growth                                                     | [61] |
| miRNA   | mir-155-5p        | GE5-1 and AGS                   | AGS                    | Promote proliferation and migration                                       | [62] |
| miRNA   | mir-301a-3p       | Hypoxia MGC803                  | MGC803 and MKN45       | Promote GC progression                                                    | [63] |
| IncRNA  | SPRY4-IT1         | BGC-823                         | MKN-28                 | Promote cell growth                                                       | [64] |
| IncRNA  | ZFAS1             | BGC-823 and MGC-803             | MKN-28                 | Enhance cell proliferation and migration                                   | [65] |
| IncRNA  | IncHeIH           | HGC-27                          | GE5-1                  | Promote GC progression                                                    | [66] |
| IncRNA  | Inc01559          | MSCs                            | HGC-27 and AGS         | Promote GC progression                                                    | [67] |
| circRNA | circNRP1          | BGC-823 and MKN-45              | BGC-823 and MKN-45     | Promote GC progression                                                    | [68] |
| circRNA | circSHKB1         | BGC-823 and HGC-27              | BGC-823 and HGC-27     | Promote GC progression                                                    | [69] |
| circRNA | circNHS1          | HGC-27 and AGS                  | HGC-27 and AGS         | Contributes to GC progression                                             | [70] |

**Abbreviations:** mBMMSC mouse bone marrow mesenchymal stem cell, MSC mesenchymal stem cell, HUVECs human umbilical vein endothelial cells, TAM tumor-associated macrophage
derived sEV-enriched miR-301a-3p could target PHD3 to inhibit HIF-1α degradation. The sEV-miR-301a-3p/HIF-1α signalling axis facilitated GC proliferation and even metastasis.

Other studies have revealed that sEVs promote tumour progression through mechanisms such as the NF-κB pathway [47], Hedgehog pathway [74], and PI3K-Akt pathway [75]. Nonetheless, the contents of sEVs that play critical roles need to be further explored.

**sEVs and angiogenesis & metastasis**

Inhibiting gastric cancer-related angiogenesis is a current targeted treatment strategy for GC, and many studies involving coculture of GC cell sEVs with human umbilical vein endothelial cells (HUVECs) have been performed (Table 2). Studies have found that miR-130a [79], miR-135b [80], miR-155 [81, 82], miR-23a [83], X26nt [89] and YB-1 [76] promote angiogenesis through different mechanisms and proposed potential targets beyond conventional targeted drug therapy. A recently published article claimed that sEVs containing miR-6785-5p could suppress angiogenesis and metastasis in GC by inhibiting INHBA [84].

The premetastatic niche, a preformed microenvironment influenced by sEVs secreted from the primary site to distal metastasis, has been reviewed in many kinds of tumours [91–93]. Substantial in vitro and preclinical models have proven that sEV-driven transfer of biomolecular cargo between tumour and normal cells potently promotes distal microenvironments that are favourable to cancer growth [94]. A previous study demonstrated that integrin αvβ5 in sEVs was associated with liver metastasis [95]. In addition, sEVs containing secretory EGFR derived from GC cells effectively activate hepatocyte growth factor, which in turn binds to c-MET receptors on migrating cancer cells to promote the homing of metastatic cancer cells. Therefore, EGFR may be beneficial to the development of a liver-like microenvironment, leading to liver-specific metastasis [77]. Moreover, miR-196a-1 could promote metastasis to the liver in vitro and in vivo via sEVs from highly invasive to low-invasive GC cells [85]. Unfortunately, no more sEV-driven molecules that can indicate organ-specific metastasis have been discovered. We will describe the the relationship between sEVs and the microenvironment later in the article.

### Table 2 Role of sEVs cargo in angiogenesis and metastasis of GC

| Type       | Contents                      | Donor cells                  | Recipient cells | Function                                                      | Ref. |
|------------|-------------------------------|------------------------------|-----------------|---------------------------------------------------------------|------|
| protein    | TRIM3                         | Overexpressed MGC-803 and SGC-7901 | MGC-803 and SGC-7901 | Suppress GC metastasis                                      | [56] |
| protein    | YB-1                          | SGC-7901                     | HUVECs          | Promote angiogenesis                                          | [76] |
| protein    | EGFR                          | SGC-7901                     | Liver cells     | Promote GC liver metastasis                                  | [77] |
| protein    | Wnt5a                         | LNM-derived GC cells         | BM-MSCs         | Maintaining tumour-promoting phenotype and function          | [78] |
| miRNA      | miR-130a                      | SGC-7901                     | HUVECs          | Promote angiogenesis and tumour growth                       | [79] |
| miRNA      | miR-135b                      | SGC-7901                     | HUVECs          | Promote angiogenesis                                         | [80] |
| miRNA      | miR-155                       | SGC-7901                     | HUVECs          | Promote growth, metastasis, and tube formation of vascular cells | [81, 82] |
| miRNA      | miR-23a                       | HGC-27                       | HUVECs          | Promote angiogenesis                                          | [83] |
| miRNA      | miR-6785-5p                    | HUVECs                       | MGC-803 and SGC-7901 | Suppress angiogenesis and metastasis                      | [84] |
| miRNA      | miR-196a-1                    | GSU and N-87                 | GSU and N-87    | Promote GC cell invasion and metastasis                      | [85] |
| miRNA      | GKN1                          | HFE-145                      | AGS and MKN1    | Suppress migration and invasion of GC cells by inhibiting epithelial-mesenchymal transition. | [71] |
| miRNA      | miR-29                        | Peritoneal fluid             | /               | Suppress growth of disseminated peritoneal tumour cells      | [86] |
| miRNA      | miR-21-5p                      | MGC-803, MKN-45, HGC-27, and SGC-7901 | PMC and HMrSV5 | Induce MMT and promote tumour peritoneal metastasis          | [87] |
| miRNA      | miR-423-5p                     | Overexpressed SGC-7901 and HGC-27 | SGC-7901 and HGC-27 | Promote GC metastasis                                      | [61] |
| miRNA      | miR-301a-3p                    | Hypoxia MGC803               | MGC803 and MKN45 | Promote GC metastasis                                         | [63] |
| lncRNA     | PCGEM1                        | HGC                           | NG              | Promote invasive and metastasis                               | [88] |
| ncRNA      | X26nt                         | MGC-803                      | HUVECs          | Increases angiogenesis and vascular permeability              | [89] |
| circRNA    | circ-RanGAP1                   | HGC-27 and AGS               | HGC-27 and AGS | Promote GC invasion and metastasis                           | [90] |
Peritoneal metastasis is a manifestation of advanced GC and often indicates a poor prognosis, and mesothelial cells function in the protective barrier of the peritoneum. EVs derived from GC can destroy the mesothelial barrier and cause peritoneal fibrosis, promoting peritoneal metastasis [96]. Similarly, miR-21-5p induced the mesothelial-to-mesenchymal transition (MMT) in peritoneal mesothelial cells and promoted peritoneal metastasis [87]. Using peritoneal lavage or ascites of patients with GC, Ohzawa et al. observed differences in the expression of miR-29 in patients with or without peritoneal metastasis; patients with low expression of miR-29b-3p had a higher peritoneal metastasis rate and a worse prognosis. MiR-29 may play an inhibitory role in the growth of diffuse peritoneal tumour cells [86].

Lymphatic metastasis is a common metastatic route of GC. Lu et al. studied the miR-877-3p/VEGFA axis mediated by circ-RanGAP1 and found that high expression of circ-RanGAP1 is closely related to TNM staging, lymphatic metastasis and poor survival [90]. A recently published study showed that bone marrow-derived mesenchymal stem cells could be specifically educated by sEVs containing Wnt5a via activation of the YAP signalling pathway [78]. This new insight into the mechanisms of lymphatic metastasis suggests potential therapeutic targets.

In addition, Piao et al. conducted a very interesting experiment in which they cocultured GC cells in conditioned medium from GC cells grown under hypoxia or normoxia and found that IncRNA PCGEM1 was highly expressed in GC cells cultured under hypoxic conditions and induced the invasion and metastasis of GC cells under normoxic conditions. This finding may be because PCGEM1 reduces the degradation of SNAI1, which in turn induces the epithelial-mesenchymal transition in GC; this finding may explain the molecular mechanism of GC cell invasion under hypoxic conditions [88]. Fu et al. discovered TRIM3 by screening the proteomic profile of serum sEVs in patients with GC and reported that it inhibits the survival and metastasis of GC in vitro and in vivo by regulating stem cell factors and EMT regulators [56].

sEVs and chemoresistance
Advanced unresectable GC usually involves comprehensive treatment based on drug therapy, commonly including chemotherapy and targeted therapy. However, in clinical practice, the same chemotherapy regimen often produces different therapeutic effects in different patients; some patients even develop chemotherapy resistance early, which is associated with poor prognosis and poses considerable therapeutic challenges. Many previous studies on the analysis of disease-related genes, combined with the molecular classification of GC, have been carried out to provide comprehensive treatment guidance for patients. With the development of sEV research in recent years, whether the contents of sEVs have an impact on chemotherapeutic resistance mechanisms and even the immune microenvironment has naturally become an emerging hot research topic [51]. sEVs might also have broad prospects for surmounting multidrug resistance in cancer [97] (Table 3).

Platinum drugs are one of the most common chemotherapy drugs used for GC, and cisplatin and oxaliplatin have been included as first-line treatments. Cisplatin-resistant gastric cancer cells communicate with sensitive cells through RPS3 in sEVs and activation of the PI3K-Akt-cofilin-1 signalling pathway [98]. Zheng et al. [99] found that M2-polarized macrophages can promote resistance to cisplatin in GC cells. sEV-miR-21 can be directly transferred from macrophages to GC cells, downregulating PTEN expressing and activating the PI3K/AKT signalling pathway to inhibit apoptosis. Moreover, a newly discovered form of iron-dependent oxidative cell death called ferroptosis is caused by lethal accumulation of lipid-based reactive oxygen species (ROS) [111], which may be related to tumour progression and drug resistance. Zhang et al. [100] found that arachidonic acid lipoxygenase 15 (ALOX15) is closely related to the production of lipid-based ROS in GC. The most valuable finding is that sEVs-miR-522 secreted by tumour-associated fibroblasts is a potential inhibitor of ALOX15, blocking the accumulation of lipid-based ROS and inhibiting ferroptosis in GC cells and thereby reducing sensitivity to chemotherapy drugs such as cisplatin and paclitaxel. Furthermore, miR-500a-3p and miR-214 are reportedly related to platinum resistance, and antimiR-214 can reverse the resistance of GC to cisplatin. Perhaps in the near future, these molecules will become adjuvant drugs for the treatment of cisplatin-resistant GC [101–104]. A similar mechanism has also been reported for oxaliplatin resistance [105].

The drug 5-fluorouracil (5-FU) is another commonly used chemotherapy agent for GC. It has been reported [106] that hypermethylation of transcription factor activation promoter-binding protein 2e (TFAP2E) is related to 5-FU resistance. Highly expressed miR-106a-5p and miR-421 regulate the drug resistance induced by TFAP2E methylation, and bioinformatics analysis predicts that E2F1, MTOR and STAT3 may be target genes. Therefore, sEV- and miRNA-related mechanisms may be used to reverse drug resistance.

Additionally, sEVs may be involved in resistance to doxorubicin [107, 108], vincristine [109] and paclitaxel [110]. However, some data seem to be from cell research and it is speculated that they may be found in sEVs as they belong to a group of molecules which are frequently found in sEVs. Therefore, more rigorous and standardized experiments are needed for verification.
### Table 3: Role of sEVs cargo in chemoresistance of GC

| Drug         | Contents | Type      | Function                                                                 | Ref.  |
|--------------|----------|-----------|--------------------------------------------------------------------------|-------|
| Cisplatin    | RPS3     | protein   | Promote the chemoresistance of cisplatin-sensitive cells                 | [98]  |
| miR-21       | miRNA    | Tumour-associated macrophages derived sEVs-miR-21 confer cisplatin resistance in GC | [99]  |
| anti-miR-214 | miRNA    | Reverse the resistance to cisplatin in GC                               | [52]  |
| miR-522      | miRNA    | Inhibit ferroptosis in cancer cells by targeting ALOX15 and blocking lipid-ROS accumulation | [100] |
| miR-500a-3p  | miRNA    | Could be a potential modality for the prediction and treatment of GC with chemoresistance | [101] |
| HOTTIP       | IncRNA   | Contribute to cisplatin resistance in GC by regulating miR-218/HMGA1 axis | [102] |
| circ-0000260 | circRNA  | Contribute to cisplatin resistance by upregulating MMP11 via targeting miR-129-5p. | [103] |
| circ-PVT1    | circRNA  | Contribute to cisplatin resistance via miR-30a-5p/YAP1 axis.            | [104] |
| Oxaliplatin  | circ-0032821 | circRNA  | Contribute to oxaliplatin resistance by regulating SOX9 via miR-515-5p | [105] |
| 5-FU         | TFP2E    | protein   | Hypermethylation of TFAP2E resulted in 5-FU chemoresistance in GC cells   | [106] |
| Doxorubicin  | miR-501  | miRNA     | Resistance to doxorubicin is possibly achieved by sEVs-miR-501-induced downregulation of BLID, subsequent inactivation of caspase-9/−3 and phosphorylation of Akt. | [107] |
| Vincristine  | CLIC1    | protein   | Induce the development of resistance to vincristine in vitro, which might relate to up-regulated P-gp and Bcl-2. | [109] |
| Paclitaxel   | miR-155-5p | miRNA    | Induce EMT and chemo-resistant phenotypes from paclitaxel-resistant GC cells to the sensitive cells, which may be mediated by GATA3 and TP53INP1 suppression. | [110] |

### Table 4: Role of sEVs cargo in the microenvironment of GC

| Type         | Contents | Donor cells | Recipient cells | Function                                                                 | Ref.  |
|--------------|----------|-------------|-----------------|--------------------------------------------------------------------------|-------|
| Protein      | HMGB1    | BGC         | Neutrophils     | Induce N2 polarization of neutrophils                                   | [50]  |
| Protein      | BMPs     | SGC-7901    | Pericytes       | Induce transition into cancer-associated fibroblasts                   | [112] |
| Protein      | CagA     | CagA-expressing WT-A10 | WT-10 and AGS | Involved in the development of extra-gastric disorders associated with CagA-positive *H. pylori* infection | [113] |
| Protein      | Apolipoprotein | TAM        | MFC and MGC- 803 | Promote cell migration                                                  | [114] |
| Protein      | MET      | H. pylori-infected AGS | TAM | Educate macrophages towards a pro-tumourigenesis phenotype            | [115] |
| Protein      | TGF-β1   | Plasma from GC patients | CD4+CD45RA+ naive T cells | Induce Treg cell differentiation                                         | [116] |
| Protein      | TGF-β    | SGC-7901 and HGC-27 | HuMSCs | Trigger differentiation to carcinoma-associated fibroblasts          | [117] |
| miRNA        | miR-21   | TAM         | BGC-823         | Contribute to cell proliferation                                         | [118] |
| miRNA        | miR-451  | MKN45       | Infiltrated T cells | Increase Th17 differentiation                                           | [119] |
| miRNA        | miR-27a  | SGC-7901    | CCC-HSF-1       | Promote transformation into cancer-associated fibroblasts             | [120] |
| miRNA        | miR-106a | AGS         | Mesothelial cells | Promote peritoneal metastasis                                           | [121] |
| miRNA        | miR-34   | Cancer-associated fibroblasts | AGS, AZ521, MKN1, and NUGC3 | Inhibit growth and invasion of GC cells                               | [122] |
| miRNA        | miR-139  | Cancer-associated fibroblasts | AGS | Inhibit GC progression                                                  | [123] |
| miRNA        | miR-30a-5p | deoxycholic acid-induced macrophage | GES-1 | Promote intestinal metaplasia and suppress proliferation              | [124] |
| miRNA        | miR-16-5p | M1 macrophages | T cells | Inhibit GC progression                                                  | [125] |
| circRNA      | ciRS-133 | SGC-7901    | 3T3L1           | Promote differentiation into brown-like cells                           | [126] |
sEVs and the microenvironment & immunotherapy

EVs can also affect the tumour microenvironment, which mainly consists of inflammatory cells, stromal cells, extracellular matrix and so on (Table 4) (Fig. 3). Tumour-associated fibroblasts (CAFs) have a vital role in tumour progression. A recent study revealed that GOF p53-containing sEVs can promote fibroblast transformation into a tumour-associated phenotype [127]. Pericytes retain the characteristics of progenitor cells and differentiate into fibroblasts under pathological conditions. EVs derived from GC cells have been shown to enhance the proliferation and migration of pericytes and induce the expression of CAF markers. The above process is affected by BMP metastasis mediated by sEVs [112]. Helicobacter pylori is one of the most important pathogenic factors of antral GC, and CagA encoded by cytotoxin-related genes is the most critical toxin of this bacterium [128]. It has been reported that sEVs secreted by gastric epithelial cells expressing CagA may enter the circulation, deliver CagA to distant organs and tissues, and participate in the development of extragastric diseases related to cagA-positive H. pylori infection [113].

The main component of the tumour microenvironment, namely, tumour-associated macrophages (TAMs), has a tendency to promote cancer. Apolipoprotein E (Apo E) is a highly specific protein secreted by M2 macrophages. Apo E is expressed in the microenvironment of GC and activates the PI3K-Akt signalling pathway to promote metastasis [114]. H. pylori also activates MET and has a pro-tumorigenic effect on TAMs [115]. However, the delivery of sEVs from TAMs contributes to cell proliferation [118]. M1 macrophage-derived sEVs containing miR-16-5p were found to trigger a T cell immune response by decreasing the expression of PD-L1, which could eventually suppress tumour progression [125].

Furthermore, sEVs affect the differentiation of T cells [116, 119] and promote transformation to carcinoma-associated fibroblasts [117, 120] and brown-like adipocytes [126]. By targeting Smad7 in peritoneal mesothelial cells, sEV-miR-106a plays a crucial role in GC peritoneal metastasis [121].

After coculture of tumour-associated fibroblasts with GC cells, the proliferation and invasion of the latter were inhibited, indicating that miRNA-34 may have tumour-
suppressor effects, but the potential target genes and mechanisms need to be determined [122]. MiR-139, which is also derived from tumour-associated fibroblasts, can inhibit the progression and metastasis of GC by negatively regulating MMP11 [123].

In addition, bile acid might participate in the process of intestinal metaplasia and gastric epithelial cell proliferation [129], but the mechanism has not been fully elucidated. Xu et al. [124] demonstrated that DCA-activated macrophages could secrete sEVs to transport miR-30a-5 to GES-1 cells, thereby affecting the above process by targeting FOXD1. Then, tumour angiogenesis might be induced via the AKT/NF-κB pathway [130].

Finally, some studies have shown the influence of sEVs in the microenvironment, but specific substances have yet to be discovered, and further investigations are needed. Hinata et al. [131] reported that sEVs secreted by Epstein-Barr virus (EBV)-associated gastric cancer cells could suppress dendritic cell maturation, thereby negatively affecting the induction of tumour immunity. Liu et al. [132] showed that GC-derived sEVs could block the cell cycle and induce CD8+ T cell apoptosis. Lung metastasis could also be promoted due to the decrease in CD8+ T cells and NK cells and the increase in CD4+ T cells and myeloid-derived suppressor cells (MDSCs). Exosome-mediated metabolic reprogramming should also be further exploited to elucidate the mechanism of GC progression [133].

sEVs have strong potential in the field of cancer immunotherapy [134]. In clinical practice, with the development of PD-1/PD-L1-related research, immunotherapy-related clinical trials have gradually been carried out in patients with MSI-H and dMMR. Tumour immunotherapy has recently been a hot research topic, with a focus on clinical research related to programmed death receptor protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, mainly for the activation and promotion of immune cells to counteract immune suppression and promote the killing effect against tumours [135]. Previous research has mainly focused on the role of soluble PD-L1, whereas there are few studies on sEV-PD-L1. Due to the secretory properties of sEVs, they can both inhibit and kill T cells in the local tumour microenvironment and be transferred to a remote site to exert other functions, which may be a powerful factor leading to tumour immune escape [136]. Fan et al. reported that due to its stability and T cell dysfunction caused by MHC-I expression, sEV-PD-L1 can reflect the immune status and predict the long-term prognosis of patients [137]. In addition, a study published in 2020 by Zhang et al. [138] stated that the use of 5-FU may upregulate the expression of sEV-PD-L1, which is likely to cause immunosuppression after more than two cycles of chemotherapy. This discovery may affect future comprehensive treatment strategies for advanced GC. It is also expected that further in-depth studies will clarify the relationship between different drug treatments and provide patients with accurate and efficient comprehensive treatment plans.

Most of the related literature has been published in the past three years, which may be due to the rapid development of proteomics and transcriptomics. With the continuous maturity of such technology, it is believed that more tumour-associated effects of sEV contents will be discovered. Of course, the proportion of tumour-associated cargo and the kind of effect sEVs produce under the action of multiple contents remain open questions.

### Application prospects of sEVs in GC

#### Diagnosis and prognostic evaluation of GC

The lipid bilayer structure of sEVs protects their cargo from degradation while maintaining a fairly constant content. The noninvasive nature, possibility for real-time assessment and stable characteristics make sEVs an ideal potential biomarker [139, 140]. An sEVs-RNA-based test for early prostate cancer detection has been included in the National Comprehensive Cancer Network (NCCN) guidelines. Indeed, an increasing number of studies have proven that sEVs have strong developmental potential and application prospects in the early diagnosis and prognostic evaluation of GC (Table 5).

The earliest high-quality study was conducted by Zhou et al. [141] in 2015. Five highly expressed microRNAs were selected and assessed in the plasma of 30 GC patients and 30 healthy people, with verification in 71 and 61 areas under the receiver operating characteristic (ROC) curve (AUC) of 0.86 and 0.74, respectively. In the subsequent external verification phase, the AUC was also as high, at 0.87. Unfortunately, a small number of patients do not show any increase in sEV microRNAs, and it may be necessary to further improve the selection of markers. In serum, high expression of membrane type 1 matrix metalloproteinase (MT1-MMP) is considered to be related to the tumour diameter, depth of invasion and TNM stage in GC. Moreover, the sEV-MT1-MMP axis has been proven to be an independent risk factor for GC lymphatic metastasis, which provides strong evidence for serological sEVs to predict the risk of lymphatic metastasis [142]. Huang et al. [143] adopted the Exiqon panel based on qRT-PCR and found 58 differentially expressed miRNAs using three GC sample banks and a normal control sample bank, and six miRNAs in serum (miR10b-5p, miR132-3p, miR185-5p, miR195-5p, miR20a-3p and miR296-5p) were selected for diagnosing GC. Other studies have also reported many new biomarkers [144–153].

In some studies, protein or DNA is the focus of sEVs detection. Yamamoto et al. [154] conducted methylation
detection using sEVs derived from GC cell lines, GC tissues and gastric juice and found higher levels of BARHL2 methylation in gastric juice from early GC patients and GC cell lines, with lower levels in normal and atrophic gastritis. Moreover, after resection of early GC via endoscopy, the methylation level was significantly reduced. The AUC of this meaningful study was 0.923, and this approach is expected to become a highly accurate method for detecting early GC. For patients with metastatic GC, Ding et al. [169] provided a

### Table 5 Application of sEVs cargo in diagnosis and prognostic evaluation of GC

| Application | Type     | Biofluids | Contents                                      | Ref.   |
|-------------|----------|-----------|-----------------------------------------------|--------|
| Diagnosis of GC | miRNA    | Plasma    | miR-185, miR-20a, miR-210, miR-25, miR-92b     | [141]  |
|             | Protein  | Serum     | GKN1                                          | [55]   |
|             | Protein  | Serum     | MT1-MMP                                       | [142]  |
|             | miRNA    | Serum     | miR10b-5p, miR195-5p, miR20a-3p, miR296-5p     | [143]  |
|             | IncRNA   | Plasma    | CEBPA-AS1                                     | [144]  |
|             | IncRNA   | Serum     | HOTTIP                                        | [145]  |
|             | IncRNA   | Serum     | GNAQ-6                                        | [146]  |
|             | miRNA    | Serum     | miR-200a-3p, miR-296-5p, miR-132-3p, miR-485-3p, miR-22-5p | [147]  |
|             | miRNA    | Plasma    | miR-217                                       | [148]  |
|             | miRNA    | Serum     | miR-92a-3p                                    | [149]  |
|             | miRNA    | Serum     | miR-590-5p                                    | [150]  |
|             | IncRNA   | Serum     | pck2k2-2-1                                    | [151]  |
|             | miRNA    | Serum     | miR-19b-3p, miR-106a-5p                       | [152]  |
|             | IncRNA   | Plasma    | LINC00152                                     | [153]  |
|             | IncRNA   | Serum     | ZFAS1                                         | [65]   |
| Diagnosis of early GC | Protein  | gastric juice | BARHL2                                       | [154]  |
|             | IncRNA   | Serum     | GC1                                           | [155]  |
|             | miRNA    | Serum     | miR-92b-3p, let-7 g-5p, miR-146b-5p, miR-9-5p | [156]  |
|             | miRNA    | Serum     | miR-1246                                      | [157]  |
|             | circRNA  | Plasma     | circ-0065149                                  | [158]  |
| Diagnosis of early GC and premalignant chronic atrophic gastritis | IncRNA | Plasma | UEGC1                                         | [159]  |
| Distinguish GC patients with various kinds of metastasis | miRNA | Plasma | miR-10b-5p, miR-101-3p, miR-143-5p              | [160]  |
| Diagnosis of malignant GC-associated ascites | miRNA | Ascites | miR-181b-5p                                  | [161]  |
| Predict the recurrence risk and prognosis of patients with GC in each stage | miRNA | Plasma | miR-23b                                       | [162]  |
| Predict the prognosis of patients with GC | miRNA | Serum | miR-423-5p                                   | [61]   |
|             | miRNA    | Serum     | miR-451                                       | [119]  |
|             | IncRNA   | Serum     | HOTTIP                                        | [145]  |
|             | circRNA  | Plasma     | circ-KIAA1244                                  | [163]  |
|             | circRNA  | Plasma     | circ-0065149                                  | [158]  |
|             | circRNA  | Plasma     | circ-SLC2A12-10:1                             | [164]  |
|             | IncRNA   | Serum     | MIAT                                          | [165]  |
| Predict the prognosis of GC and risk of lymphatic metastasis | IncRNA | Serum | ZFAS1                                         | [65]   |
|             | Protein  | Serum     | MT1-MMP                                       | [142]  |
| Correlate with tumour stage, lymphatic and distal metastasis, venous and perineural invasion. | circRNA | Serum | circ-0000419                                 | [166]  |
| Predict postoperative haematogenous metastasis of stage II/III GC | miRNA | Serum | miR-379-5p, miR-410-3p                        | [167]  |
| Predict the peritoneal metastases | miRNA | Ascites | miR-21-5p, miR-92a-3p, miR-223-3p, miR-342-3p | [168]  |
comprehensive description of the serum sEVs-proteome and found that several subunits might act as biomarkers and therapeutic targets.

In addition, lncRNAs and circRNAs have become important research molecules in recent years. In July 2020, a multistage study of 522 patients with GC, 85 patients with precancerous lesions of the stomach and 219 healthy people was published [155]. Subsequently, lncRNA-GC1 was found to be significantly elevated in GC cell culture medium, as confirmed in those with precancerous lesions and healthy people. As lncRNA-GC1 is almost exclusively secreted by sEVs, the level of lncRNA-GC1 can remain stable after ribonuclease treatment, even after prolonged exposure to room temperature or repeated freezing and thawing. Various studies have shown that this molecule is likely to become an ideal noninvasive GC diagnostic biomarker. In the future, the combination of lncRNA-GC1 detection and gastroscopy will substantially improve the early diagnosis rate of GC. Zhao et al. [145] analysed serological sEVs from 246 subjects and found that the expression level of HOTTIP in GC was high, with a higher diagnostic ability than CEA, CA 19–9 and CA72–4 (P < 0.001). Similarly, lncUEG1 in sEVs has been confirmed to have a high sensitivity in the diagnosis of GC, which is expected to promote early GC screening in the future [159]. Other studies have contributed to the early diagnosis of GC [156–158].

Zhang et al. [160] used second-generation sequencing technology to obtain the RNA sequencing spectrum of GC patients for the first time and reported that miR-10b-5p, miR-101-3p and miR-143-5p could be used to distinguish lymphatic metastasis, ovarian metastasis and liver metastasis of GC. Such an early and accurate predictive method is conducive to the examination and evaluation of distant organs by clinicians as well as to the early detection of metastatic lesions, which is of practical value. By screening several microRNAs differentially expressed in GC patients and controls followed by further analysis and screening, researchers can use multiple microRNAs in combination for diagnosis and prognostic evaluation. From the perspective of GC ascites identification, Yun et al. used a microarray to detect the expression level of miRNAs in 73 cases of liver cirrhosis-related ascites and 92 cases of gastric cancer-related ascites and found that miR-181b-5p was superior to CEA in the diagnosis of GC ascites. When the two were used in combination, notable areas under the curve of 0.981 and 0.946 were achieved in the training and validation groups, respectively, revealing an excellent method of distinguishing the properties of ascites [161]. Kumata et al. [162] elaborated on the role of sEV-miRNAs in predicting the recurrence of GC: using miRNA chips, they found that miR-23b is specific for recurrence, and its ability to predict recurrence and prognosis at various tumour stages was fully demonstrated in 232 GC patients and 20 healthy volunteers.

Benefiting from their stable properties, sEV containing circRNAs have achieved remarkable results as biomarkers [158, 163–166]. CircRNA expression profile analysis of the plasma from GC patients at different TNM stages and healthy people showed lower circ-KIAA1244 in GC tissues, plasma and cell lines [163]. Through further clinical data analysis, it was found that decreased expression of circ-KIAA1244 correlated negatively with TNM staging and lymphatic metastasis, and the overall survival of such patients was significantly shortened. Subsequently, circ-0000419 was reported to be significantly related to tumour staging, distant metastasis, and venous and nerve infiltration. Both of them may become powerful indicators for early GC screening and prognostic evaluation of advanced GC. The risk of postoperative haematogenous metastasis of stage II/III GC [167] and peritoneal metastases [168] might also be predicted.

In ongoing clinical trials, sEVs are considered biomarkers of cancer diagnosis and prognosis. By monitoring changes in sEVs-HSP70 in the circulation, tumour response and clinical outcome could be predicted (NCT02662621 [170]). There are also two clinical trials focusing on the possibility of circulating sEVs as prognostic markers in advanced GC (NCT01779583) and digestive cancer (NCT04530890) without posted results.

Studies of sEVs as molecular markers are ongoing, and their biological characteristics contribute to the theoretical basis of clinical applications. Several websites have been developed to exhibit potential biomarkers for cancer diagnosis and prognosis [18, 171]. However, a literature review can reveal that early detection technology is dated and expensive, resulting in the small scale of the research to date [139]. As such, sample selection bias is impossible to avoid, which leads to uneven results. In recent years, with the government’s support for big-data platforms, the continuous upgrading of detection technologies and the gradual decline in detection costs, an increasing number of large-sample sequencing studies have been carried out to promote the implementation of sEV biomarkers in clinical practice.

**Cancer drug delivery, antitumour vaccines and engineered sEVs**

Efficient delivery and targeting of therapeutic cargo need to be achieved to combat tumours, and sEVs can be used as drug delivery vehicles due to their unique physiochemical characteristics, high bioavailability and low nontargeted cytotoxicity [172].

Proton pump inhibitors (PPIs) are commonly used drugs to inhibit gastric acid secretion, and their antitumour potential is gradually being discovered. Guan et al. [173] found that high-dose PPIs can inhibit the release
of sEVs and regulate the HIF-1α-FOXO1 axis, thereby regulating the tumour microenvironment and improving the prognosis of patients with advanced GC.

In the present literature, cancer cell-derived sEVs could preferentially fuse with their parent cancer cells [174]. Many sEVs have been used as carriers for antitumour proteins or microRNA inhibitors because of their tissue penetration, nonimmunogenicity, and cell tropism [175]. At present, only two clinical trials have explored the drug-carrying capacity of natural EVs, and they have not produced the expected results (NCT01294072 and NCT01854866). However, the number of patents based on EVs is still low; thus, further research is still warranted [176].

sEVs, especially exosomes, have now entered vaccine development [177, 178]. Numerous studies have shown that tumour-derived exosomes (TEXs) could have immunosuppressive effects as well as immunostimulatory effects [179–181]. Antitumour vaccines based on sEVs have been used to suppress tumour growth through dendritic cell-released MHC class I/peptide complexes for efficient CD8+ T cell priming [182]. Cheng et al. also demonstrated that sEVs derived from M1-polarized macrophages have the potential to be used as vaccine adjuvants due to their ability to home to lymph nodes and the expression of proinflammatory T helper cell type 1 cytokines [183]. For exploration of the feasibility of exosomes as immunotherapeutic vaccines, several clinical trials have been carried out or will be carried out (NCT01159288, NCT01550523 and NCT03608631). However, application of these treatments in GC is still progressing slowly.

Although natural EVs can elicit antitumour activities, there are still several problems. Accurate dose monitoring and targeted biodistribution in vivo are difficult to realize due to the high heterogeneity and complicated components of natural EVs, which lead to reduced therapeutic efficacy and safety concerns [184]. Therefore, artificial engineered sEVs have been generated through genetic and chemical methods to improve antitumour efficacy [185, 186].

Various strategies have been used for sEV engineering, of which loading target cargo or modification are two major strategies [187]. Cargo active loading into donor cells and direct loading into sEVs are the main components of the former [188]. In addition to constantly developing general modifications of EV membranes [189],

---

**Figure 4** sEVs play a significant role in gastric cancer carcinogenesis and progression (a), angiogenesis and metastasis (b), chemoresistance (c), microenvironment and immunotherapy (d). sEVs can be applied in diagnosis and prognostic evaluation (e), and other future aspects (f).
new engineered EV-based platforms, such as EV-mimetic nanovesicles [190] and artificially synthesized EV-like synthetic nanoparticles [191], have gradually been developed.

There have been several animal models to investigate the utility of EVs for cancer drug delivery. For gastric cancer, sEVs containing anti-miR-214 could strengthen chemosensitivity and inhibit tumour growth in a cisplatin-resistant gastric cancer mouse model [52]. Pan et al. demonstrated that PMA/Au-BSA@Ce6 nanoparticles containing HLA-A2 and several costimulatory molecules could activate CD8+ T cells to strengthen the effectiveness of immunotherapy [193]. Unfortunately, there is no research on sEVs in the chemotherapy of gastric cancer.

As shown above, although the application of sEVs has been extensively and profoundly explored in many cancers, further studies on this topic in gastric cancer are needed. We drew a compass-shaped diagram to show the role and application of sEVs in gastric cancer intuitively (Fig. 4). It is urgent to advance our understanding of sEVs to unlock their full potential in the prevention and treatment of gastric cancer. In addition, it also urgent to set up reliable assays to assess the therapeutic potential of sEVs, and to develop such assays into formal potency tests for clinical application [194].

Conclusion
Extensive attention has been paid to EVs in recent years. This research expands our understanding of the functions of sEVs and the mechanism of tumorigenesis and provides a new perspective for the prevention and treatment of gastric cancer. The mechanism of action of gastric cancer-related sEVs mainly depends on their complex cargo. In addition, communication between GC cells and the tumour microenvironment, as well as many unknown mechanisms and molecules, adds to the overall complexity and uncertainty.

Of course, opportunities and challenges coexist. The complicated cargo emphasizes the complexity of the mechanism, and the dominant roles of the various molecules and the mechanisms of the comprehensive effect are still unknown. Limited by immature technology, the diversity of detection methods and results, and the high cost of detection, few large-sample, multicentre studies have been conducted to date. Moreover, the genetic differences between East and West, between countries, and even between regions are likely to challenge the universality of existing research. Thus, prior to the clinical application of scientific results, there is an urgent need for further evaluation of the safety, effectiveness and stability of sEVs, and clinicians, pharmacists, and other professional scientists need to work together. Regardless, it is foreseeable that due to their unique biological characteristics, sEVs will become an important tool in the near future for accurate early diagnosis and personalized and efficient treatment of tumours, providing infinite power to overcome cancers.

Abbreviations
GC: Gastric cancer; sEVs: small extracellular vesicles; EVs: Extracellular vesicles; MISEV: Minimal Information for Studies of Extracellular Vesicles; ESCR: Endosomal sorting complex required for transport; miRNA: microRNA; circRNA: circular RNA; lncRNA: long noncoding RNA; MVB: Multivesicular bodies; MSC: Mesenchymal stem cell; CAF: Cancer-associated fibroblast; EMT: Epithelial mesenchymal transition; H. pylori: Helicobacter pylori; TAM: Tumour-associated macrophage; TNF-α: Tumour necrosis factor alpha; GMCSF: Granulocyte-macrophage colony stimulating factor; IL: Interleukin; PMC: Peritoneal mesothelial cell; 5-FU: 5-Fluorouracil; HUVECs: Human umbilical vein endothelial cells; GRK1: Gastrokine 1; FZD10: Frizzled 10; UBR2: N-recognin 2; MMT: Mesothelial-to-mesenchymal transition; AUC: Area under curve; ROC: Receiver operating characteristic; MT1-MMP: Membrane type 1 matrix metalloproteinase; ALOX15: Arachidonic acid lipoygenase 15; TFAP2E: Transcription factor activation promoter binding protein 2e; Apo E: Apolipoprotein E; MDSC: Myeloid-derived suppressor cell; PD-1: Programmed death receptor protein 1; PD-L1: Programmed death-ligand 1; PPI: Proton pump inhibitors; NCCN: National Comprehensive Cancer Network.
Shandong University, Jinan 250021, Shandong, China. 3Department of Gastroenterology, Shandong Provincial Hospital, Cheeolo College of Medicine, Shandong University, Jinan 250021, Shandong, China. 4Department of Gastroenterological Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China. 5Department of Digestive Tumor Translational Medicine, Engineering Laboratory of Shandong Province, Shandong Provincial Hospital, Jinan 250021, Shandong, China.

Received: 11 January 2021 Accepted: 19 April 2021 Published online: 29 April 2021

References

1. Hung S, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.

2. Fu M, Gu J, Jiang P, Qian H, Xu W, Zhang X. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol Cancer. 2019;18:41.

3. Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer. 2019;18:62.

4. Thery C, Witwer KW, Akawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISE V2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.

5. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967–78.

6. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8:727.

7. Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function, and potential clinical use in renal diseases. Braz J Med Biol Res. 2013;46:824–30.

8. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A. 2003;100:10592–7.

9. Fang Y, Wu N, Gan Y, Yan W, Morrell JC, Gould SJ. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 2007;5:e158.

10. Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myelodysplastic suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12:84.

11. Wei D, Zhan W, Gao Y, Huang L, Wang W, et al. RA831 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2020;31:157–70.

12. Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Extracellular vesicles (EVs) in colorectal cancer. J Exp Clin Cancer Res. 2019;38:150.

13. Li Y, Zhang X, Li J, et al. Exosome-based theranostics. Theranostics. 2020;10:3684–707.

14. Nkosi J, Du Preez NP, Boyce MJ, et al. Proteomic profiling of exosome cargo identifies potential diagnostic and therapeutic biomarkers in patients with colorectal cancer. J Proteomics. 2019;208:103500.

15. Mashouri L, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18:75.

16. Li Y, Zhao J, Yu S, Wang Z, He X, Su Y, et al. Extracellular vesicles Long RNA controls an ESCRT-independent exosome pathway. Cell Res. 2020;31:157–70.

17. Makarova J, Turchinovich A, Shkurnikov M, Tonevitsky A. Extracellular vesicles Long RNA promotes tumor cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009;41:875–80.

18. Li Y, Li C, Trojanowska M, Li X, Sh D, Zhan C, et al. CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 2016;19:554–66.

19. Li C, Liu DR, Li GG, Wang HH, Li XW, Zhang W, et al. CD97 promotion of gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. World J Gastroenterol. 2015;21:6215–28.
46. Tanaka M, Kuriyama S, Itoh G, Maeda D, Goto A, Tamiya Y, et al. Mesothelial cells create a novel tissue niche that facilitates gastric Cancer invasion. Cancer Res. 2017;77:684–95.
47. Wu L, Zhang X, Zhang B, Shi H, Yuan X, Sun Y, et al. Exosomes derived from gastric cancer cells activate NF-kappaB pathway in macrophages to promote cancer progression. Tumor Biol. 2016;37:12169–80.
48. Fang F, Li B, Wei Y, Zhao Y, Wang L, Zhang P, et al. Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression. Oncogenesis. 2018;7:411.
49. Shen Y, Xue C, Li X, Ba L, Gu J, Sun Z, et al. Effects of gastric Cancer cell-derived Exosomes on the immune regulation of Mesenchymal stem cells by the NF-kB signaling pathway. Stem Cells Dev. 2019;28:464–75.
50. Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17:146.
51. Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015;14:2473–8.
52. Wang X, Zhang H, Bai M, Ning T, Ge S, Deng T, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse Chemoresistance to Cisplatin in gastric cancer. Mol Ther. 2018;26:774–83.
53. Scavo MP, Depalo N, Rizzi F, Ingrosso C, Fanizza E, Chieti A, et al. Fzd10 carried by Exosomes sustains Cancer cell proliferation. Cells. 2019;8:777.
54. Mao J, Liang Z, Zhang B, Yang H, Li X, Fu H, et al. UBR2 enriched in p53 – derived exosomes promote progression and metastasis via MiR-301a-3p/TPIP expression. Pathol Res Pract. 2020;216:152986.
55. Yoon JH, Ham IH, Kim O, Ashktorab H, Smoot DT, Nam SW, et al. Gastrokine PHD3/HIF-1α positive feedback loop. Oncogene. 2020;39:6231–41.
56. Mao J, Liang Z, Zhang B, Yang H, Li X, Fu H, et al. UBR2 enriched in p53 – derived exosomes promote progression and metastasis via MiR-301a-3p/TPIP expression. Pathol Res Pract. 2020;216:152986.
57. Wu et al. Molecular Cancer (2021) 20:71
58. Huang J, Shen M, Yan M, Cui Y, Gao Z, Meng X. Exosome-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 2017;143:991–1004.
59. Lu Y, Hou K, Li M, Wu X, Yuan S. Exosome-delivered LincHEIH promotes gastric Cancer progression by Upregulating Ezh2 and stimulating the methylation of the GSDME promoter. Front Cell Dev Biol. 2020;8:571297.
60. Wang L, Bo X, Xu X, Xiao A, Zheng N, Ma L, et al. Exosome-transferred UNC155 promotes the progression of gastric cancer via PI3K/AKT signaling pathway ay. Cell Death Dis. 2020;11:723.
61. Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, et al. Circular RNA circRPP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019;18:20.
Peinado H, Alekovic M, Latovshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91.

Feng W, Dean DC, Hornick JF, Shi H, Duan Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer. 2019;18:124.

Moller A, Lobbi R. J. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20:697–709.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Nagamine T, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35.

Geng D, Qu J, Zhang Y, Che X, Cheng Y, Fan Y, et al. Gastric cancer-derived exosomes promote peri-tumoral metastasis by destroying the mesothelial barrier. F1000Res. 2017;5:2167–79.

Lepetit E, Rijo P, Rizzolli F, Popovtzer R, Petitkova V, Assaf YG, et al. Nanomedicine to target multidrug resistant tumors. Drug Resist Updat. 2020;52:100704.

Sun MY, Xu B, Wu QX, Chen WL, Cal S, Zhang H, et al. Cisplatin-resistant gastric cancer cells promote the chemoresistance of Cisplatin-sensitive cells via the Exosomal RFS3-mediated PDK-Akt-Colluin-1 signaling Axis. Front Cell Dev Biol. 2021;9:618899.

Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36:53.

Zhang H, Deng T, Liu R, Ding T, Yang H, Liu D, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;20:1943.

Lin H, Zhang L, Zhang C, Liu P. Exosomal miR-503a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020;24:8930–41.

Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-mediated transfer of InRncRNA HOTTIP promotes Cisplatin resistance in gastric Cancer cells by regulating HMGAI/miR-218 Axis. Oncol Targets Ther. 2019;12:11325–38.

Liu S, Wu M, Peng M. Circ_000265 regulates the development and deterioration of gastric adenocarcinoma with Cisplatin resistance by Upregulating MMP11 via targeting miR-129-5p. Cancer Manag Res. 2020;12:10505–19.

Yao W, Guo P, Wu Q, Wang Y. Exosome-derived Circ-PVT1 contributes to Cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p/YAP1 Axis in gastric Cancer cells. Cancer Biol Ther. 2020;21:89.

Zhong Y, Wang D, Ding Y, Tian G, Jiang B. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by repressing MMP11 expression. Int J Biol Sci. 2019;15:2320–9.

Xu X, Cheng J, Luo S, Huang D, Xu J, Qian Y, et al. Deoxysphoric acid-stimulated macrophage-derived exosomes promote intestinal metastasis and suppress prf derepression in human gastric epithelial cells. Eur J Pharmacol. 2020;887:173566.

Liu S, Xiao M, Kong G, Yao Y, Li Z, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric Cancer. Front Cell Dev Biol. 2020;8:572689.

Zheng H, Zhu L, Bai M, Liu Y, Zhan Y, Deng T, et al. Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PDM16 pathway. Int J Cancer. 2019;144:2501–15.

Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, et al. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021;34:108726.

Hatakeyama M. Oncogenic mechanisms of the helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4:688–94.

Li T, Guo H, Li H, Jiang Y, Zhuang K, Lei C, et al. MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal remodeling. Cell Death Dis. 2019;10:572.

Chen C, Xu ZQ, Zong YP, Ou BC, Shen XF, Feng H, et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019;10:178.

Hinata M, Kunita A, Abe H, Morishita Y, Sakuma K, Yamashita H, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35.

Ning X, Zhang H, Wang C, Song X. Exosomes released by gastric Cancer cells induce transition of Pericytes into Cancer-associated fibroblasts. Med Sci Monit. 2018;24:3505–9.

Shimoda A, Ueda K, Nishiyama S, Murata-Kamya N, Nakai S, Sawada S, et al. Exosomes as nanocarriers for systemic delivery of the helicobacter pylori virulence factor CagA. Sci Rep. 2016;6:18346.

Zheng P, Luo Q, Wang W, Li J, Wang T, Wang P, et al. Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apollipoprotein E. Cell Death Dis. 2018;9:19434.
149. Lu X, Lu J, Wang S, Zhang Y, Ding Y, Shen X, et al. Circulating serum
147. Wang J, Zhang H, Zhou X, Wang T, Zhang J, Zhu W, et al. Five serum-based
146. Li S, Zhang M, Zhang H, Hu K, Cai C, Wang J, et al. Exosomal long
145. Zhao R, Zhang Y, Zhang X, Yang Y, Zheng X, Li X, et al. Exosomal long
158. Shao Y, Tao X, Lu R, Zhang H, Ge J, Xiao B, et al. Hsa_circ_0065149 is an
154. Yamamoto H, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Maehata T, et al.
153. Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L, et al. Plasma long
152. Wang N, Wang L, Yang Y, Gong L, Xiao B, Liu X. A serum exosomal
159. Lin LY, Yang L, Zeng Q, Wang L, Chen ML, Zhao ZH, et al. Tumor-originated
144. Piao HY, Guo S, Wang Y, Zhang J. Exosomal Long non-coding RNA CEBPA-
141. Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang F, et al. Diagnostic value of a
139. Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al.
Wu et al. Molecular Cancer (2021) 20:71

Page 18 of 19
185. Jayasinghe MK, Tan M, Peng B, Yang Y, Sethi G, Pirisinu M, et al. New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies. Semin Cancer Biol. 2021.

186. Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11:3183–95.

187. Zhang X, Zhang H, Gu J, Zhang J, Shi H, Qian H, et al. Engineered extracellular vesicles for Cancer therapy. Adv Mater. 2021;33:e2005709.

188. Eshkarky OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev. 2020;159:332–43.

189. Pham TC, Jayasinghe MK, Pham TT, Yang Y, Wei L, Usman WM, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracellular Vesicles. 2021;10:e12057.

190. Wang J, Li W, Zhang L, Ban L, Chen P, Du W, et al. Chemically edited Exosomes with dual ligand purified by microfluidic device for active targeted drug delivery to tumor cells. ACS Appl Mater Interfaces. 2017;9:27441–52.

191. Nasiri Kenari A, Cheng L, Hill AF. Methods for loading therapeutics into extracellular vesicles and generating extracellular vesicle mimetic-nanovesicles. Methods. 2020;177:103–13.

192. Pan S, Pei L, Zhang A, Zhang Y, Zhang C, Huang M, et al. Passion fruit-like exosome-PMA/au-BSA@Ce6 nanovehicles for real-time fluorescence imaging and enhanced targeted photodynamic therapy with deep penetration and superior retention behavior in tumor. Biomaterials. 2020;230:119606.

193. Kim S, Sohn HJ, Lee HJ, Sohn DH, Hyun SJ, Cho HJ, et al. Use of engineered Exosomes expressing HLA and Costimulatory molecules to generate antigen-specific CD8+ T cells for adoptive cell therapy. J Immunother. 2017;40:4083–93.

194. Nguyen VVT, Witwer KW, Verhaar MC, Strunk D, van Balkom BWM. Functional assays to assess the therapeutic potential of extracellular vesicles. J Extracellular Vesicles. 2020;10:e12033.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.